Mobile website
Clinical Research
Treatment efficacy and safety profile of Nab-paclitaxel and carboplatin combined with antiangiogenic drugs as salvage regimen in advanced melanoma patients
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To evaluate the treatment efficacy and safety profile of NCA regimen (nab-paclitaxel, carboplatin and antiangiogenic drug) in advanced melanoma patients who failed previous therapy. Methods: We retrospectively enrolled the melanoma patients who were treated in the Department of Melanoma of Peking University Cancer Hospital from April 1, 2012 to March 31, 2019 and investigated the efficacy and safety of NCA regimen in unresectable stage IIIC or IV melanoma patients who failed previous therapy. The primary endpoint was the progression-free survival (PFS), and the secondary indicators were objective response rate (ORR), overall survival (OS), disease control rate (DCR) and adverse reactions. The patients were divided into endostatint treatment group (Endo-arm, n=73) and bevacizumab treatment group (Beva-arm, n=103) according to the antiangiogenic drug used in the regimen. Propensity score matching was applied to balance the differences in baseline covariates between different antiangiogenic drug groups. Results: Overall, 176 patients were included in this study. The median age of included patients was 51 years old (18-78). Stage IV patients accounted for 97%. There were 50% patients with higher LDH level than normal, and 28% patients with liver metastasis. The proportions of lines of previous treatment were 57% for first line treatment, 33% for second line and 10% for third-fourth line. The median PFS was 3.8 months (95% CI: 3.0–4.6 m) and median OS was 10.5 months (95% CI: 8.9-12.1 m) in overall study population. There were 9 PR (partial remission) cases and 2 CR (complete remission) cases, yielding an overall ORR of 6% with a DCR of 70%. The median PFS of Endo-arm and Beva-arm was 4.7 months (95%CI:3.5~5.9m) and 3.4 months (95%CI: 3.0~4.6m) respectively, while the median OS was 12.2 months (95%CI: 11.1~13.2m) and 9.1 months (95%CI: 7.8~10.4m) respectively. After the age, gender, lines of previous treatment and LDH level of patients were adjusted by propensity score matching, there were no statistical differences in PFS and OS between Beva-arm and Endo-arm. Common adverse events included alopecia, peripheral neuropathy, neutropenia, fatigue and nausea. 26 patients (15%) discontinued treatment adverse events. Conclusion: The NCA regimen shows modest antitumor effects in melanoma patients who failed previous treatment, due to and the adverse reactions were acceptable.
Keywords:
Project Supported:
Project suppoted by the National Natural Science Foundation of China (No.81972566; No.82073011; No.81972562), the Beijing Natural Science Foundation (No.7202024), the Ascent Plan of Beijing Municipal Administration of Hospitals (No.DFL20181101), the Clinical Medicine Plus X-Young Scholars Project of Peking University (No.PKU2019LCXQ017), the Beijing Medical Award Foundation (No.YXJL-2020-0889-0106), and the CSCO-CSCP Oncology Research Foundation (No.Y-SY201901-0270)
Clc Number:
